PH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma

Luis A. Serrano, Ye Yang, Elisa Salvati, Francesco Stellacci, Silke Krol, Stefan Guldin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

At present, drug dosage is based on standardised approaches that disregard pharmakokinetic differences between patients and lead to non-optimal efficacy and unnecessary side effects. In this work, we demonstrate the potential of pH-mediated fluorescence spectroscopy for therapeutic drug monitoring in complex media. We apply this principle to the simultaneous quantification of the chemotherapeutic prodrug Irinotecan and its active metabolite SN-38 from human plasma across the clinically relevant concentration range, i.e. from micromolar to nanomolar at molar ratios of up to 30:1.

Original languageEnglish
Pages (from-to)1485-1488
Number of pages4
JournalChemical Communications
Volume54
Issue number12
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

irinotecan
Drug dosage
Plasma (human)
Fluorescence spectroscopy
Metabolites
Monitoring
Prodrugs
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry

Cite this

PH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma. / Serrano, Luis A.; Yang, Ye; Salvati, Elisa; Stellacci, Francesco; Krol, Silke; Guldin, Stefan.

In: Chemical Communications, Vol. 54, No. 12, 01.01.2018, p. 1485-1488.

Research output: Contribution to journalArticle

Serrano, LA, Yang, Y, Salvati, E, Stellacci, F, Krol, S & Guldin, S 2018, 'PH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma', Chemical Communications, vol. 54, no. 12, pp. 1485-1488. https://doi.org/10.1039/c7cc07668a
Serrano, Luis A. ; Yang, Ye ; Salvati, Elisa ; Stellacci, Francesco ; Krol, Silke ; Guldin, Stefan. / PH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma. In: Chemical Communications. 2018 ; Vol. 54, No. 12. pp. 1485-1488.
@article{dd3031866f604b3fb9e9d2b38dac4e15,
title = "PH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma",
abstract = "At present, drug dosage is based on standardised approaches that disregard pharmakokinetic differences between patients and lead to non-optimal efficacy and unnecessary side effects. In this work, we demonstrate the potential of pH-mediated fluorescence spectroscopy for therapeutic drug monitoring in complex media. We apply this principle to the simultaneous quantification of the chemotherapeutic prodrug Irinotecan and its active metabolite SN-38 from human plasma across the clinically relevant concentration range, i.e. from micromolar to nanomolar at molar ratios of up to 30:1.",
author = "Serrano, {Luis A.} and Ye Yang and Elisa Salvati and Francesco Stellacci and Silke Krol and Stefan Guldin",
year = "2018",
month = "1",
day = "1",
doi = "10.1039/c7cc07668a",
language = "English",
volume = "54",
pages = "1485--1488",
journal = "Chemical Communications",
issn = "1359-7345",
publisher = "Royal Society of Chemistry",
number = "12",

}

TY - JOUR

T1 - PH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma

AU - Serrano, Luis A.

AU - Yang, Ye

AU - Salvati, Elisa

AU - Stellacci, Francesco

AU - Krol, Silke

AU - Guldin, Stefan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - At present, drug dosage is based on standardised approaches that disregard pharmakokinetic differences between patients and lead to non-optimal efficacy and unnecessary side effects. In this work, we demonstrate the potential of pH-mediated fluorescence spectroscopy for therapeutic drug monitoring in complex media. We apply this principle to the simultaneous quantification of the chemotherapeutic prodrug Irinotecan and its active metabolite SN-38 from human plasma across the clinically relevant concentration range, i.e. from micromolar to nanomolar at molar ratios of up to 30:1.

AB - At present, drug dosage is based on standardised approaches that disregard pharmakokinetic differences between patients and lead to non-optimal efficacy and unnecessary side effects. In this work, we demonstrate the potential of pH-mediated fluorescence spectroscopy for therapeutic drug monitoring in complex media. We apply this principle to the simultaneous quantification of the chemotherapeutic prodrug Irinotecan and its active metabolite SN-38 from human plasma across the clinically relevant concentration range, i.e. from micromolar to nanomolar at molar ratios of up to 30:1.

UR - http://www.scopus.com/inward/record.url?scp=85042046233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042046233&partnerID=8YFLogxK

U2 - 10.1039/c7cc07668a

DO - 10.1039/c7cc07668a

M3 - Article

AN - SCOPUS:85042046233

VL - 54

SP - 1485

EP - 1488

JO - Chemical Communications

JF - Chemical Communications

SN - 1359-7345

IS - 12

ER -